Publications by authors named "Sergio Traversa"

Claim this Profile
E
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Maurizio Fava, Stephen M Stahl, Luca Pani, Sara De Martin, Andrew J Cutler, Sergio Traversa

J Clin Psychiatry· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei

Drugs R D· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Franco Folli

Drugs R D· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
Maurizio Fava, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Sergio Traversa

Eur Arch Psychiatry Clin Neurosci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
Megan J Shram, Jack E Henningfield, Glen Apseloff, Charles W Gorodetzky, Sara De Martin, Sergio Traversa

Transl Psychiatry· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
Stephen M Stahl, Sara De Martin, Andrea Mattarei, Ezio Bettini, Luca Pani, Sergio Traversa

Int J Mol Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
Ezio Bettini, Stephen M Stahl, Sara De Martin, Andrea Mattarei, Jacopo Sgrignani, Sergio Traversa

Pharmaceuticals (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
Jack Henningfield, David Gauvin, Francesco Bifari, Reginald Fant, Megan Shram, Sergio Traversa

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin.
Ezio Bettini, Sara De Martin, Andrea Mattarei, Marco Pappagallo, Stephen M Stahl, Sergio Traversa

Pharmaceuticals (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.
Francesco Bifari, Marco Pappagallo, Michael Bleavins, Sergio Traversa, Franco Folli

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Maurizio Fava, Stephen Stahl, Luca Pani, Sara De Martin, Marco Pappagallo, Sergio Traversa

Am J Psychiatry· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.
Sara De Martin, Daniela Gabbia, Franco Folli, Francesco Bifari, Paolo Fiorina, Sergio Traversa

Front Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis